Latest news with #CarmelMonaghan
Yahoo
13-06-2025
- Business
- Yahoo
ASX Penny Stocks: EMVision Medical Devices Leads Our Trio Of Picks
As Australian shares are set to advance slightly, buoyed by positive U.S. inflation data and a stable commodities market, investors are keenly observing the opportunities within the local stock landscape. Despite its vintage feel, the term 'penny stocks' continues to hold relevance for those interested in smaller or newer companies that offer both affordability and growth potential. In this article, we explore three penny stocks that stand out for their financial strength and potential for long-term value creation. Name Share Price Market Cap Financial Health Rating EZZ Life Science Holdings (ASX:EZZ) A$1.735 A$81.85M ★★★★★★ GTN (ASX:GTN) A$0.605 A$115.47M ★★★★★★ IVE Group (ASX:IGL) A$2.76 A$425.54M ★★★★★☆ Southern Cross Electrical Engineering (ASX:SXE) A$1.67 A$441.56M ★★★★★★ Tasmea (ASX:TEA) A$3.10 A$730.43M ★★★★★☆ Regal Partners (ASX:RPL) A$2.22 A$746.28M ★★★★★★ Accent Group (ASX:AX1) A$1.805 A$1.09B ★★★★☆☆ Lindsay Australia (ASX:LAU) A$0.705 A$223.61M ★★★★☆☆ Bisalloy Steel Group (ASX:BIS) A$3.27 A$155.16M ★★★★★★ CTI Logistics (ASX:CLX) A$1.79 A$144.17M ★★★★☆☆ Click here to see the full list of 1,006 stocks from our ASX Penny Stocks screener. Underneath we present a selection of stocks filtered out by our screen. Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: EMVision Medical Devices Ltd focuses on the research, development, and commercialization of neurodiagnostic technology for stroke diagnosis and monitoring, along with other medical imaging needs in Australia, with a market cap of A$156.92 million. Operations: The company generates revenue primarily from the research and development of medical device technology, amounting to A$8.06 million. Market Cap: A$156.92M EMVision Medical Devices Ltd, with a market cap of A$156.92 million, remains pre-revenue as it focuses on developing its neurodiagnostic technology. The company has more cash than debt and maintains a stable cash runway exceeding one year. Recent developments include the commencement of a pivotal trial for its emu™ Brain Scanner, aimed at stroke diagnosis and potentially supporting FDA clearance. This trial could pave the way for future product expansions in the medical imaging field. EMVision's board recently welcomed Carmel Monaghan as an Independent Non-Executive Director, bringing extensive healthcare experience to support strategic growth initiatives. Unlock comprehensive insights into our analysis of EMVision Medical Devices stock in this financial health report. Explore historical data to track EMVision Medical Devices' performance over time in our past results report. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: LGI Limited focuses on carbon abatement and renewable energy solutions using biogas from landfill, with a market cap of A$267.31 million. Operations: The company generates revenue from Carbon Abatement (A$17.03 million), Renewable Energy (A$15.05 million), and Infrastructure Construction and Management (A$2.21 million). Market Cap: A$267.31M LGI Limited, with a market cap of A$267.31 million, is generating revenue from Carbon Abatement (A$17.03 million), Renewable Energy (A$15.05 million), and Infrastructure Construction and Management (A$2.21 million). Despite the company's earnings contracting by 15.3% over the past year, its debt management remains strong with operating cash flow covering 34.4% of its debt and a reduced debt-to-equity ratio from 146.5% to 46.2% over five years. While LGI's net profit margin has decreased to 17.4%, it maintains stable weekly volatility at 4%. The board is experienced, though management tenure averages only 1.3 years. Click here to discover the nuances of LGI with our detailed analytical financial health report. Understand LGI's earnings outlook by examining our growth report. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: NRW Holdings Limited, with a market cap of A$1.36 billion, offers diversified contract services to the resources and infrastructure sectors in Australia through its subsidiaries. Operations: NRW Holdings generates revenue from three main segments: Mining at A$1.56 billion, MET at A$853.22 million, and Civil at A$776.06 million. Market Cap: A$1.36B NRW Holdings, with a market cap of A$1.36 billion, demonstrates strong financial health through well-covered interest payments and operating cash flow that exceeds its debt by a large margin. The company's earnings have grown significantly by 29.9% over the past year, surpassing both its historical average and industry growth rates. Despite having low return on equity at 17.3%, NRW is trading below estimated fair value and has not diluted shareholders recently. Short-term assets exceed liabilities, indicating robust liquidity management, while recent executive changes bring seasoned leadership to the finance team with Peter Bryant as CFO starting in May 2025. Navigate through the intricacies of NRW Holdings with our comprehensive balance sheet health report here. Evaluate NRW Holdings' prospects by accessing our earnings growth report. Click this link to deep-dive into the 1,006 companies within our ASX Penny Stocks screener. Looking For Alternative Opportunities? The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 25 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ASX:EMV ASX:LGI and ASX:NWH. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
The Australian
05-06-2025
- Business
- The Australian
EMVision adds Ramsay Health Care boss to board
Ramsay Health Care Australia CEO Carmel Monaghan joins board of EMVision Medical Devices Monaghan has worked across hospital, corporate and global positions at Ramsay for almost three decades Appointment comes as EMVision progresses pivotal trial for emu bedside brain scanner to diagnose stroke Special Report: The CEO of Ramsay Health Care, Australia's largest private hospital operator, has joined the board of EMVision Medical devices as a non-executive director. With her appointment effective today, Carmel Monaghan, who has been CEO of Ramsay Health Care (ASX:RHC) Australia since 2020, joins the board of EMVision Medical Devices (ASX:EMV) at a pivotal time in its commercial journey. Ramsay is Australia's largest private hospital operator and offers a range of multidisciplinary healthcare services. It also has extensive operations internationally including in the UK and Europe. Monaghan has worked across hospital, corporate and global positions at Ramsay for almost three decades. Before her appointment as CEO, Monaghan was group chief of staff of Ramsay's global operations, gaining extensive experience and a comprehensive understanding of healthcare operations and strategy both in Australia and overseas. EMVision said she also served as the group head of marketing and public affairs, driving marketing, brand and communications strategy, during which time the group grew to become a leading private healthcare operator globally. Appointment follows start of pivotal trial Monaghan's appointment comes after the company kicked off a pivotal trial in March for its first commercial device – the emu bedside brain scanner, which is designed to rapidly diagnose stroke at the point-of-care. The pivotal trial supports US Food and Drug Administration (FDA) de novo (new device) clearance for emu. If granted clearance emu is anticipated to become the predicate device for its second device, First Responder, allowing an expedited 510(k) FDA pathway for the pre-hospital market. EMVision this week announced it had broadened the pivotal trial for its first commercial device with activation at Mount Sinai Hospital in New York, scheduled for this month. Mount Sinai is recognised as a leader in stroke research and treatment. Activation of another site – Liverpool Hospital in Sydney, is in progress this Hospital is recognised as one of the largest stroke referral centres in New South Wales. All up, five world-leading hospitals are now taking part in EMVision's pivotal trial with a sixth set to be activated shortly. Watch: EMVision expands trial for bedside stroke scanner A 'transformative opportunity' Monaghan said she looks forward to working with management and fellow directors as the company enters a pivotal phase in its commercialisation journey. 'After more than three decades in healthcare leadership, I'm especially drawn to opportunities where innovation directly addresses unmet patient needs,' she said. 'Stroke and traumatic brain injury are leading causes of global disability and disease burden and will increase with an ageing population. 'Timely access to acute care and treatment are crucial in minimising the impact of stroke and so I'm excited by the transformative opportunity that EMVision's point-of-care neurodiagnostic products represent to improve outcomes for patients.' EMVision chairman John Keep said Monaghan was an 'exceptional addition' to EMVision's board. 'She brings a wealth of experience across clinician engagement, corporate strategy, marketing, procurement and government relations,' he said. 'With our pivotal trial for regulatory clearance underway, the board looks forward to Carmel's contributions as EMVision progresses through to commercialisation and growth.' This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.
